AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8436150 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 2430269 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 1% creme rinse
Number of subjects: 0
Study 2430269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2430269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Lindane shampoo
Number of subjects: 0
Study 31638977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile learning readiness
Number of subjects: 332
Study 31638977 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude
Number of subjects: 332
Study 31638977 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral control
Number of subjects: 332
Study 31638977 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject norm
Number of subjects: 332
Study 31638977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TPB structures (attitude, behavioral control, subject norm)
Number of subjects: 332
Study 29402670 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple vessel (MV) group
Number of subjects: 78
Study 29402670 — intervention group
Group type: COMPARATOR
Intervention: Single vessel (SV) group
Number of subjects: 78
Study 26817533 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa‐carbidopa intestinal gel
Number of subjects: 167
Study 26817533 — intervention group
Group type: COMPARATOR
Intervention: oral levodopa treatment
Number of subjects: 167
Study 25359307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (Yi‐Qi‐Jian‐Pi and Qu‐Tan‐Hua‐Zhuo granule) plus conventional medicine
Number of subjects: 240
Study 25359307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (Yi‐Qi‐Jian‐Pi and Qu‐Tan‐Hua‐Yu granule) plus conventional medicine
Number of subjects: 240
Study 25359307 — intervention group
Group type: COMPARATOR
Intervention: Placebo medicine plus conventional medicine
Number of subjects: 240
Study 25359307 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both treatment and control)
Number of subjects: 240
Study 22897374 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 % O2 + 60 % N2O, 1‐2 % sevoflurane and 50 µg fentanyl + 2 mg vecuronium every 45 minutes
Number of subjects: 40
Study 22897374 — intervention group
Group type: COMPARATOR
Intervention: 60 % dry air instead of 60 % N2O
Number of subjects: 40
Study 20708634 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers with class S allele (L/S or S/S genotypes)
Number of subjects: 504
Study 20708634 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers (L/L genotype)
Number of subjects: 504
Study 20708634 — intervention group
Group type: EXPERIMENTAL
Intervention: L/S genotype
Number of subjects: 504
Study 20708634 — intervention group
Group type: EXPERIMENTAL
Intervention: S/S genotype
Number of subjects: 504
Study 18826032 — intervention group
Group type: EXPERIMENTAL
Intervention: BioUD (7.75% 2-undecanone)
Number of subjects: 0
Study 18826032 — intervention group
Group type: COMPARATOR
Intervention: 7% deet
Number of subjects: 0
Study 18826032 — intervention group
Group type: COMPARATOR
Intervention: 15% deet
Number of subjects: 0
Study 17186975 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 44
Study 17186975 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 44
Study 12963549 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHI
Number of subjects: 22
Study 12963549 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 22
Study 10693982 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control program for lipid testing at St. Paul's Hospital, UBC and NPHI, Helsinki.
Number of subjects: 0
Study 10693982 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control program for triglyceride measurements at UBC and NPHI.
Number of subjects: 0
Study 10693982 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control program for HDL measurements at UBC and NPHI.
Number of subjects: 0
Study 10693982 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control program for apoprotein A‐1 measurements at both laboratories.
Number of subjects: 0
Study 10693982 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control program for apoprotein B measurements at both laboratories.
Number of subjects: 0
Study 10693982 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAMAT assay for hemoglobin A‐1c at both laboratories.
Number of subjects: 0
Study 9487427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin containing short‐course antituberculosis regimens
Number of subjects: 49
Study 9487427 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lymphocytes < 1200/microliters
Number of subjects: 49
Study 9487427 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ lymphocytes < 200/microliters
Number of subjects: 49
Study 9487427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavitary lung disease
Number of subjects: 49
Study 9487427 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical chest radiograph
Number of subjects: 49
Study 9487427 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD non‐reactivity
Number of subjects: 49
Study 9487427 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD non‐reactivity and non‐cavitary disease
Number of subjects: 49
Study 8398959 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 ml interscalene brachial plexus block with 1.5% mepivacaine, epinephrine, and bicarbonate
Number of subjects: 20
Study 8398959 — intervention group
Group type: COMPARATOR
Intervention: 20 ml interscalene brachial plexus block with 1.5% mepivacaine, epinephrine, and bicarbonate
Number of subjects: 20
Study 2439803 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 12
Study 2439803 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bisoprolol
Number of subjects: 12
Study 2439803 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 12
Study 2439803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2439803 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study 29781549 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets administered before transport to surgery
Number of subjects: 122
Study 29781549 — intervention group
Group type: COMPARATOR
Intervention: No platelets (control)
Number of subjects: 122
Study 27842532 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg
Number of subjects: 62
Study 27842532 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN plus RBV
Number of subjects: 62
Study 23867557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz TMS to the right primary motor cortex (M1)
Number of subjects: 0
Study 23867557 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 0
Study 23742725 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight barley β-glucan (HBG)
Number of subjects: 15
Study 23742725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight barley β-glucan (LBG)
Number of subjects: 15
Study 23742725 — intervention group
Group type: COMPARATOR
Intervention: Control soup with no barley β-glucan (CHO)
Number of subjects: 15
Study 20562409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpotomy with calcium‐enriched mixture (PCEM), n = 205
Number of subjects: 407
Study 20562409 — intervention group
Group type: COMPARATOR
Intervention: One-visit root canal therapy (ORCT), n = 202
Number of subjects: 407
Study 20562409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpotomy with calcium‐enriched mixture (PCEM)
Number of subjects: 407
Study 20562409 — intervention group
Group type: COMPARATOR
Intervention: One-visit root canal therapy (ORCT)
Number of subjects: 407
Study 18091041 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-component intervention including e-mail memoranda, a Web site, and a handheld computer program.
Number of subjects: 16500
Study 18091041 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (remaining hospitals in the county).
Number of subjects: 16500
Study 16398773 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg oral misoprostol
Number of subjects: 338
Study 16398773 — intervention group
Group type: COMPARATOR
Intervention: 400 microg self-administered vaginal misoprostol
Number of subjects: 338
Study 12927624 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formula diet with long-chain triglycerides (LCT)
Number of subjects: 10
Study 12927624 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formula diet with medium-chain triglycerides (MCT)
Number of subjects: 10
Study 12927624 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (4.1 +/- 0.5 mg) administered for 90 min
Number of subjects: 10
Study 10807893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 kcal/ml nutritional supplement
Number of subjects: 101
Study 10807893 — intervention group
Group type: COMPARATOR
Intervention: Routine nutritional management (Control)
Number of subjects: 101
Study 8795595 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU of interferon-beta-1a
Number of subjects: 68
Study 8795595 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MIU of interferon-beta-1a
Number of subjects: 68
Study 1516606 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 8
Study 1516606 — intervention group
Group type: COMPARATOR
Intervention: absence of levodopa
Number of subjects: 8
Study 6736345 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximally aggressive erythemogenic UVB (MAEUVB) schedule
Number of subjects: 0
Study 6736345 — intervention group
Group type: EXPERIMENTAL
Intervention: Suberythemogenic UVB (SEUVB) schedule
Number of subjects: 0
Study 6736345 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with 2% crude coal tar ointment
Number of subjects: 0
Study 6736345 — intervention group
Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 0
Study 31887854 — intervention group
Group type: EXPERIMENTAL
Intervention: BEYNEX (web-based program)
Number of subjects: 120
Study 31887854 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine patch (10 cm² = 9.5 mg)
Number of subjects: 120
Study 27634952 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator plus Solitaire stent retriever
Number of subjects: 69
Study 25670764 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (30 mg/m²) followed by carboplatin (AUC 5 mg min/ml) every 28 days
Number of subjects: 35
Study 25670764 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin and carboplatin
Number of subjects: 35
Study 23792243 — intervention group
Group type: EXPERIMENTAL
Intervention: Child selective attention to pain (dot-probe task)
Number of subjects: 59
Study 23792243 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental characteristics (rumination and helplessness)
Number of subjects: 59
Study 23792243 — intervention group
Group type: EXPERIMENTAL
Intervention: Child attentional avoidance
Number of subjects: 59
Study 21668741 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 142
Study 21668741 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (0.016 mg/kg)
Number of subjects: 142
Study 21668741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 142
Study 19526210 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 1024
Study 19526210 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 1024
Study 17005060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask PEP
Number of subjects: 17
Study 17005060 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 17
Study 17005060 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 17
Study 17005060 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (directed cough)
Number of subjects: 17
Study 17005060 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV and CPAP
Number of subjects: 17
Study 17005060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask PEP, CPAP, NPPV
Number of subjects: 17
Study 15383185 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 254
Study 15383185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 12024755 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-type aerosol reduction device (ARD)
Number of subjects: 15
Study 12024755 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) antimicrobial rinse
Number of subjects: 15
Study 12024755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ARD and CHX rinse
Number of subjects: 15
Study 12024755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study 9263319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 2.5% cream once daily + water-in-oil cream once daily
Number of subjects: 25
Study 9263319 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 2.5% cream twice daily
Number of subjects: 25
Study 8500857 — intervention group
Group type: COMPARATOR
Intervention: KCl infusions (0.12 and 0.24 mEq/min) with ouabain (2 micrograms/min)
Number of subjects: 0
Study 8500857 — intervention group
Group type: COMPARATOR
Intervention: KCl infusions (0.12 and 0.24 mEq/min) after salt loading (180 mEq NaCl for 7 days)
Number of subjects: 0
Study 8500857 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside and verapamil
Number of subjects: 0
Study 3791366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiorinal with Codeine
Number of subjects: 0
Study 3791366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3791366 — intervention group
Group type: COMPARATOR
Intervention: Fiorinal alone
Number of subjects: 0
Study 3791366 — intervention group
Group type: COMPARATOR
Intervention: Codeine alone
Number of subjects: 0
Study 30849351 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nylon dressing
Number of subjects: 657
Study 30849351 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 657
Study 28433895 — intervention group
Group type: EXPERIMENTAL
Intervention: peer educator network‐oriented intervention
Number of subjects: 232
Study 28433895 — intervention group
Group type: COMPARATOR
Intervention: standard of care control arm
Number of subjects: 232
Study 24957977 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min repetitive typing task
Number of subjects: 24
Study 24957977 — intervention group
Group type: COMPARATOR
Intervention: 20 min mental recitation (control)
Number of subjects: 24
Study 24037566 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical repair (OR)
Number of subjects: 189
Study 24037566 — intervention group
Group type: COMPARATOR
Intervention: Endovascular repair (EVAR)
Number of subjects: 189
Study 24037566 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (OR + EVAR)
Number of subjects: 189
Study 24037566 — intervention group
Group type: COMPARATOR
Intervention: Comparison between OR and EVAR
Number of subjects: 189
Study 22123319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 82
Study 22123319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 82
Study 22123319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (both doses)
Number of subjects: 82
Study 19903780 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (110 microg) with multipeptide vaccine
Number of subjects: 121
Study 19903780 — intervention group
Group type: COMPARATOR
Intervention: Multipeptide vaccine without GM-CSF
Number of subjects: 121
Study 19903780 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipeptide vaccine with GM-CSF
Number of subjects: 121
Study 19903780 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 121
Study 19903780 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 121
Study 16518754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated IFN‐alpha 2a and ribavirin combination therapy
Number of subjects: 0
Study 15542102 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis LKM512 yogurt (100g/day for 2 weeks)
Number of subjects: 7
Study 15542102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100g/day for 2 weeks)
Number of subjects: 7
Study 15542102 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LKM512 yogurt vs. placebo
Number of subjects: 7
Study 12184546 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D treatment (VD(+))
Number of subjects: 63
Study 12184546 — intervention group
Group type: COMPARATOR
Intervention: No treatment (VD(-))
Number of subjects: 63
Study 9640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-plus-innovative intervention
Number of subjects: 0
Study 9640634 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study 7867317 — intervention group
Group type: EXPERIMENTAL
Intervention: CCMD-2
Number of subjects: 254
Study 7867317 — intervention group
Group type: COMPARATOR
Intervention: DSM-III-R
Number of subjects: 254
Study 2801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein diet (400 kcal/d, 13.2 g nitrogen, 23 mmol potassium)
Number of subjects: 11
Study 2801579 — intervention group
Group type: COMPARATOR
Intervention: Glucose diet (400 kcal/d, 16 mmol potassium chloride, multivitamin supplement)
Number of subjects: 11
Study 1102148 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol (100 mug into each nostril twice daily)
Number of subjects: 30
Study 1102148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31516032 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg once daily plus low-dose cytarabine
Number of subjects: 0
Study 31516032 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib plus cytarabine and daunorubicin (7 + 3)
Number of subjects: 0
Study 31516032 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib plus azacitidine
Number of subjects: 0
Study 31516032 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus low-dose cytarabine
Number of subjects: 0
Study 31516032 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cytarabine and daunorubicin (7 + 3)
Number of subjects: 0
Study 31516032 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus azacitidine
Number of subjects: 0
Study 27519188 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading using ball attachments (Group A)
Number of subjects: 155
Study 27519188 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading after 3 months (Group B)
Number of subjects: 155
Study 25967143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1943
Study 25967143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1943
Study 25967143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1943
Study 25967143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib and Sorafenib
Number of subjects: 1943
Study 25967143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib, Sorafenib, and Placebo
Number of subjects: 1943
Study 23432600 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (20 mg of omeprazole, 500 mg of clarithromycin, and 1000 mg of amoxicillin orally two times daily)
Number of subjects: 2000
Study 23432600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (omeprazole plus identical placebo)
Number of subjects: 2000
Study 23432600 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 2000
Study 23432600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 21310819 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) for 4 weeks
Number of subjects: 22
Study 21310819 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 22
Study 19583746 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (1.8 mg)
Number of subjects: 0
Study 19583746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17179269 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 20 mL of 0.375% levobupivacaine
Number of subjects: 32
Study 15140661 — intervention group
Group type: EXPERIMENTAL
Intervention: PDPVT
Number of subjects: 42
Study 15140661 — intervention group
Group type: COMPARATOR
Intervention: PD
Number of subjects: 42
Study 15140661 — intervention group
Group type: COMPARATOR
Intervention: PD+PP
Number of subjects: 42
Study 11843383 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 144
Study 11843383 — intervention group
Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium
Number of subjects: 144
Study 9514542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 36
Study 9514542 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 36
Study 7913766 — intervention group
Group type: EXPERIMENTAL
Intervention: Block-replace regimen of carbimazole plus thyroxine for 6 months
Number of subjects: 100
Study 7913766 — intervention group
Group type: EXPERIMENTAL
Intervention: Block-replace regimen of carbimazole plus thyroxine for 12 months
Number of subjects: 100
Study 7913766 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA markers analysis
Number of subjects: 100
Study 30172099 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg daily oral edoxaban
Number of subjects: 1400
Study 30172099 — intervention group
Group type: COMPARATOR
Intervention: VKA-based therapy (international normalized ratio: 2.0-3.0 or 1.6-2.6 in Japan if age ≥ 70 years)
Number of subjects: 1400
Study 30172099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both edoxaban and VKA-based therapy
Number of subjects: 1400
Study 25796586 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training of the hip-flexors (dominant leg) performed three times 10 min per week for 6 weeks, progressing from 15 repetition maximum (RM) to 8 RM.
Number of subjects: 33
Study 25796586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no strength training).
Number of subjects: 33